Daratumumab for the treatment of multiple myeloma

Abstract : Proteasome inhibitors and immunomodulatory drugs have contributed to the dramatic improvement in survival for patients with myeloma over the past decades. However, the disease typically relapses and new classes of drugs are needed. In 2015, two monoclonal antibodies were approved for the treatment of patients with relapsed multiple myeloma, and immunotherapy has rapidly become indispensable in the management of myeloma patients. Areas covered: Here, the authors discuss the published data regarding the mechanism of action, safety and clinical efficacy of the CD38-targeted monoclonal antibody daratumumab for the treatment of patients with multiple myeloma. Expert opinion: Daratumumab is indicated for myeloma patients who have received at least 3 prior therapies, including bortezomib, lenalidomide and pomalidomide. In 2016, daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone was approved for the treatment of patients with multiple myeloma who have received at least one prior therapy. Daratumumab displays an excellent safety profile. Moderate-grade infusion-related reactions occurring mostly during the first infusion are the main treatment-emergent adverse event. In the context of daratumumab therapy, attention should be paid to interference with blood compatibility testing and response assessment. Daratumumab-based combination therapies are currently under evaluation in relapsed and newly diagnosed patients.
Document type :
Journal articles
Complete list of metadatas

Cited literature [49 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01819113
Contributor : Elizabeth Bernardo <>
Submitted on : Wednesday, June 20, 2018 - 9:05:55 AM
Last modification on : Thursday, February 7, 2019 - 2:53:56 PM
Long-term archiving on : Tuesday, September 25, 2018 - 12:24:53 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Cyrille Touzeau, Philippe Moreau. Daratumumab for the treatment of multiple myeloma. Expert Opinion on Biological Therapy, Informa Healthcare, 2017, 17 (7), pp.887 - 893. ⟨10.1080/14712598.2017.1322578⟩. ⟨inserm-01819113⟩

Share

Metrics

Record views

80